Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Neotame has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Review work on non-caloric sweeteners and the gut microbiome describes shifts in bacterial species composition across the sweetener class. Whether neotame specifically alters the survival or colonisation of an administered probiotic strain has not been measured. The mechanism is plausible because both act in the same compartment. Read it as an open question, not a demonstrated interaction.
Inulin is fermented by colonic bacteria into short-chain fatty acids. Non-nutritive sweeteners are described in review literature as altering the composition of that same bacterial community. Any net effect on fermentation would depend on which populations shift and by how much. This has not been tested for neotame, and pairing them is a formulation decision rather than a demonstrated synergy.
Neotame has a slow onset and a lingering finish, so formulators blend it with faster-onset sweeteners to shape the sweetness curve. Blends also let each component sit at a lower level than it would alone. This is well established industrial practice with a clear sensory rationale. It says nothing about physiological effect.
Aspartame is hydrolysed in the gut to release free phenylalanine, which is why it carries a warning for people with phenylketonuria. Neotame's bulky N-3,3-dimethylbutyl group sterically blocks the peptidases that would perform that cleavage, so very little free phenylalanine is liberated. That structural difference is the whole point of the molecule and the reason its regulatory labelling differs from aspartame's. The relationship is chemical, not a nutritional pairing.
Neotame is used at concentrations thousands of times below sugar, so on its own it leaves a powder or beverage with no body. A bulking polyol restores the volume and texture that sugar would have contributed. The two occupy different roles in the same formula. This is manufacturing convention with a straightforward physical basis.
Nothing specific on file for Neotame. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 3 we read for Neotame. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.